



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



NBQX

Cat. No.:	HY-15068		
CAS No.:	118876-58-7		
Molecular Formula:	C ₁₂ H ₈ N ₄ O ₆ S		
Molecular Weight:	336.28		
Target:	iGluR		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 75 mg/mL (223.03 mM)
H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.9737 mL	14.8686 mL	29.7371 mL
	5 mM		0.5947 mL	2.9737 mL	5.9474 mL
	10 mM		0.2974 mL	1.4869 mL	2.9737 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity^[1].

IC₅₀ & Target

AMPA receptor^[1]

In Vitro	NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	NBQX (FG9202; 20 mg/kg, i.p.; for 3 days) decreases seizures induced by PTZ^[2]. NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Wistar rats that weighed 220-240 g with pentylenetetrazole (PTZ) ^[2]
	Dosage:	20 mg/kg
	Administration:	IP; for 3 days
	Result:	Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50mg/kg; i.p.; for 28 days) in rats.

CUSTOMER VALIDATION

- Nat Med. 2019 Feb;25(2):337-349.
- Theranostics. 2023 May 11;13(9):2946-2961.
- J Neurochem. 2022 Jul 1.
- Sci Rep. 2024 Mar 12;14(1):6011.
- Neural Plast. 08 Jul 2021.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84.

[2]. Wen Chen, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016 Nov 23;11(11):e0166672.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA